Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Catherine J. Wu, MD


Medical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Chief, Division of Stem Cell Transplantation and Cellular Therapies
  • Lavine Family Chair for Preventative Cancer Therapies
  • Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Acute myeloid leukemia
  • Chronic lymphoblastic leukemia
  • Chronic myeloid leukemia
  • Sickle cell anemia
  • Stem cell transplantation
  • Tumor antigens

Contact Information

  • Appointments617-632-6140
  • Office Phone Number617-632-5943
  • Fax617-632-6380

Bio

Dr. Wu received her MD from Stanford University School of Medicine in 1994. She completed postgraduate training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology and hematology at Dana-Farber/Partners CancerCare. In 2000, she joined Dana-Farber, where she currently leads the Division of Stem Cell Transplantation and Cellular Therapies. Her research interests include the identification of targets of the immune response associated with therapies and dissecting the basis of effective human antitumor responses.

Board Certification:

  • Hematology, 2002
  • Internal Medicine, 1997
  • Medical Oncology, 2001

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology & Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Stanford University School of Medicine

Recent Awards:

  • National Academy of Medicine, Member, 2019
  • Claire W. and Richard P. Morse Research Award, DFCI, 2017
  • The One Hundred, Massachusetts General Hospital Cancer Center, 2017
  • Medical Oncology Discovery Award, DFCI, 2015
  • American Society for Clinical Investigation, Member, 2012

Research

My ongoing research studies focus on how best to effectively mount human immune responses to recognize and eradicate cancer, with dedicated effort on the discovery and targeting of tumor antigens. A longstanding theme of my studies has been how best to launch immunotherapeutic efforts in a personalized fashion, initially through studies in the area of hematopoietic stem cell transplantation (HSCT) together with whole tumor cell vaccination and more recently through the implementation of personal neoantigen-targeting cancer vaccines (Ott & Hu Nature 2017; NCT 01970358). Key to our antigen discovery efforts has been our pioneering of approaches to leverage the recent availability of next-generation massively parallel sequencing technologies to perform comprehensive genomic dissection of leukemia cells. Our efforts have led to the discovery of key mutated genes and pathways involved in the pathogenesis of chronic lymphocytic leukemia (CLL) (N Engl J Med 2011), understanding of the vast clonal heterogeneity of leukemia samples and its impact on clonal evolution (Cell 2013), and the development of resistance to therapy (Nature 2015). We have further leveraged these sequencing technologies to pioneer computational tools for the comprehensive discovery of potential personal tumor-specific neoantigens. Neoantigens are a promising novel class of cancer targets created by the personal mutations found in each patient’s tumor which we have demonstrated in first-in-human trials for advanced melanoma and glioblastoma (Nature 2017, Nature 2019).  Because these mutations generate peptides that are distinct from “self”-peptides, the resulting epitopes are expected to escape the immune dampening effects of central tolerance.  As a physician-scientist with deep insight into how to bridge important basic discoveries with questions of high clinical relevance, I am committed to dedicating our efforts on the critical question of addressing the challenge of understanding the basis of disease progression and of therapeutic resistance in blood malignancies.

Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Adv. 2021 Sep 28.
View in: PubMed

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat Commun. 2021 09 13; 12(1):5395.
View in: PubMed

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
View in: PubMed

Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021 Aug 25.
View in: PubMed

Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Mol Cell Proteomics. 2021 Aug 12; 20:100133.
View in: PubMed

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986.
View in: PubMed

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125.
View in: PubMed

Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clin Cancer Res. 2021 Sep 15; 27(18):5062-5071.
View in: PubMed

Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history. Cancer Discov. 2021 Jun 10.
View in: PubMed

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10; 137(23):3212-3217.
View in: PubMed

60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Res. 2021 Sep 01; 81(17):4373-4384.
View in: PubMed

Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discov. 2021 Sep; 11(9):2266-2281.
View in: PubMed

Splice it up: Atypical transcripts to boost leukemia immunotherapy. Immunity. 2021 04 13; 54(4):608-610.
View in: PubMed

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 May 10; 39(5):632-648.e8.
View in: PubMed

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8.
View in: PubMed

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
View in: PubMed

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
View in: PubMed

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
View in: PubMed

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in: PubMed

Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525.
View in: PubMed

Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 04; 18(4):199-214.
View in: PubMed

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 Sep 15; 27(18):5038-5048.
View in: PubMed

Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 Sep 15; 27(18):5049-5061.
View in: PubMed

Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2(1):54-69.
View in: PubMed

Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020 12; 8(12):1465-1469.
View in: PubMed

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
View in: PubMed

Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
View in: PubMed

High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biol. 2020 10 20; 21(1):266.
View in: PubMed

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in: PubMed

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in: PubMed

Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Res. 2020 11 01; 80(21):4854-4867.
View in: PubMed

Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat Biotechnol. 2021 04; 39(4):451-461.
View in: PubMed

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307.
View in: PubMed

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in: PubMed

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
View in: PubMed

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802.
View in: PubMed

Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. J Clin Invest. 2020 04 01; 130(4):1595-1607.
View in: PubMed

Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat Commun. 2020 03 18; 11(1):1438.
View in: PubMed

Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020 02; 10(2):185-197.
View in: PubMed

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020 06; 34(6):1599-1612.
View in: PubMed

Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723.
View in: PubMed

A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020 02; 38(2):199-209.
View in: PubMed

Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res. 2020 03 15; 26(6):1359-1371.
View in: PubMed

Clonal dynamics in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):466-475.
View in: PubMed

Clonal dynamics in chronic lymphocytic leukemia. Blood Adv. 2019 11 26; 3(22):3759-3769.
View in: PubMed

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019 Nov 01; 5(11):1631-1633.
View in: PubMed

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
View in: PubMed

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020 05; 105(5):1379-1390.
View in: PubMed

RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat Protoc. 2019 08; 14(8):2571-2594.
View in: PubMed

SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496.
View in: PubMed

Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479.
View in: PubMed

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019 05; 569(7757):576-580.
View in: PubMed

Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2019 Aug; 30(8):799-811.
View in: PubMed

Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat Commun. 2019 04 23; 10(1):1874.
View in: PubMed

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019 09; 33(9):2183-2194.
View in: PubMed

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019 04; 9(4):476-481.
View in: PubMed

Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. Am J Hematol. 2019 04; 94(4):446-454.
View in: PubMed

Dissecting CLL through high-dimensional single-cell technologies. Blood. 2019 03 28; 133(13):1446-1456.
View in: PubMed

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5.
View in: PubMed

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
View in: PubMed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in: PubMed

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432.
View in: PubMed

Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018 11 22; 10(1):87.
View in: PubMed

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in: PubMed

A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921.
View in: PubMed

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
View in: PubMed

Immunotherapy for glioblastoma: going viral. Nat Med. 2018 08; 24(8):1094-1096.
View in: PubMed

DeTiN: overcoming tumor-in-normal contamination. Nat Methods. 2018 07; 15(7):531-534.
View in: PubMed

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8.
View in: PubMed

TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018; 7(7):e1442999.
View in: PubMed

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
View in: PubMed

Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 2018 06; 8(6):730-749.
View in: PubMed

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185.
View in: PubMed

Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 03; 18(3):168-182.
View in: PubMed

SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell. 2017 11 13; 32(5):716-716.e1.
View in: PubMed

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
View in: PubMed

High-dimension single-cell analysis applied to cancer. Mol Aspects Med. 2018 02; 59:70-84.
View in: PubMed

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017 07 10; 32(1):1-3.
View in: PubMed

An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
View in: PubMed

Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311.
View in: PubMed

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med. 2017 Apr 03; 7(4).
View in: PubMed

Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J. 2017 Mar/Apr; 23(2):115-124.
View in: PubMed

Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity. 2017 02 21; 46(2):315-326.
View in: PubMed

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
View in: PubMed

Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493.
View in: PubMed

Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 Mar 20; 35(9):984-993.
View in: PubMed

Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008.
View in: PubMed

Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096.
View in: PubMed

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep. 2017 Feb; 19:42-45.
View in: PubMed

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
View in: PubMed

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206.
View in: PubMed

Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417.
View in: PubMed

Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in: PubMed

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
View in: PubMed

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
View in: PubMed

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in: PubMed

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25; 351(6280):1463-9.
View in: PubMed

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clin Cancer Res. 2016 Apr 01; 22(7):1547-9.
View in: PubMed

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
View in: PubMed

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015 Nov; 33(11):1152-8.
View in: PubMed

Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22; 526(7574):525-30.
View in: PubMed

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 09; 350(6257):207-211.
View in: PubMed

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015 Jul 23; 126(4):445-53.
View in: PubMed

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
View in: PubMed

Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015 Apr; 15(4):201-15.
View in: PubMed

Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15; 160(1-2):48-61.
View in: PubMed

Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825.
View in: PubMed

Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. J Clin Invest. 2014 Nov; 124(11):4681-3.
View in: PubMed

Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3:e29311.
View in: PubMed

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
View in: PubMed

Evolving understanding of the CLL genome. Semin Hematol. 2014 Jul; 51(3):177-87.
View in: PubMed

Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98.
View in: PubMed

Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69.
View in: PubMed

Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology. 2014; 3:e28187.
View in: PubMed

HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9.
View in: PubMed

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21.
View in: PubMed

Boosting leukemia-specific T cell responses in patients following stem cell transplantation. Oncoimmunology. 2013 Nov 01; 2(11):e26587.
View in: PubMed

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45.
View in: PubMed

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in: PubMed

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
View in: PubMed

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in: PubMed

Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013; 5(5):47.
View in: PubMed

SF3B1 mutations in chronic lymphocytic leukemia. Blood. 2013 Jun 06; 121(23):4627-34.
View in: PubMed

Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013 Jul; 1(1):11-5.
View in: PubMed

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
View in: PubMed

An overview of the BioCreative 2012 Workshop Track III: interactive text mining task. Database (Oxford). 2013; 2013:bas056.
View in: PubMed

BioCreative-2012 virtual issue. Database (Oxford). 2012; 2012:bas049.
View in: PubMed

The eFIP system for text mining of protein interaction networks of phosphorylated proteins. Database (Oxford). 2012; 2012:bas044.
View in: PubMed

Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. . 2012 Dec 12; 12(12):6498-504.
View in: PubMed

CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012 Nov 15; 120(20):4117-8.
View in: PubMed

Recent advances in biocuration: meeting report from the Fifth International Biocuration Conference. Database (Oxford). 2012; 2012:bas036.
View in: PubMed

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in: PubMed

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
View in: PubMed

CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 Feb; 62(2):347-57.
View in: PubMed

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72.
View in: PubMed

Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
View in: PubMed

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in: PubMed

Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines. Front Biosci (Landmark Ed). 2012 Jan 01; 17:635-55.
View in: PubMed

Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S151-60.
View in: PubMed

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
View in: PubMed

Components of the hematopoietic compartments in tumor stroma and tumor-bearing mice. PLoS One. 2011 Mar 25; 6(3):e18054.
View in: PubMed

Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
View in: PubMed

Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother. 2011 Jun; 60(6):857-67.
View in: PubMed

Data processing and analysis for protein microarrays. Methods Mol Biol. 2011; 723:337-47.
View in: PubMed

In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011 Jan; 96(1):13-5.
View in: PubMed

A coprecipitation-based validation methodology for interactions identified using protein microarrays. Methods Mol Biol. 2011; 723:239-54.
View in: PubMed

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
View in: PubMed

Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39.
View in: PubMed

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in: PubMed

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
View in: PubMed

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
View in: PubMed

Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res. 2009 Jul 15; 15(14):4515-7.
View in: PubMed

Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1270-8.
View in: PubMed

Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
View in: PubMed

A concentration-dependent analysis method for high density protein microarrays. J Proteome Res. 2008 May; 7(5):2059-68.
View in: PubMed

Allogeneic stem cell transplantation for the treatment of hemoglobinopathies. Stem Cell Transplantation for Hematologic Malignancies. 2008.

Immunologic targeting of the cancer stem cell. The Stem Book. 2008.

Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
View in: PubMed

Integration of bioinformatics resources for functional analysis of gene expression and proteomic data. Front Biosci. 2007 Sep 01; 12:5071-88.
View in: PubMed

Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
View in: PubMed

Proteome informatics for cancer research: from molecules to clinic. Proteomics. 2007 Mar; 7(6):976-91.
View in: PubMed

Target discovery using proteomic microarrays. BIOforum Europe. 2007; 11(10):20-22.

Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006; 90:133-73.
View in: PubMed

Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
View in: PubMed

Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11.
View in: PubMed

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in: PubMed

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in: PubMed

Inflammatory myopathy associated with imatinib mesylate therapy. J Clin Neuromuscul Dis. 2004 Mar; 5(3):119-21.
View in: PubMed

Antibody response to BCMA in patients with multiple myeloma. 12th International Congress of Immunology and 4th Annual Conference of FOCIS. 2004; 355-63.

A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol. 2004 Jan 01; 172(1):651-60.
View in: PubMed

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in: PubMed

Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct; 31(10):924-33.
View in: PubMed

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5.
View in: PubMed

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in: PubMed

CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522.
View in: PubMed

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in: PubMed

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in: PubMed

Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
View in: PubMed

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7.
View in: PubMed

A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7.
View in: PubMed

The immunocompromised host. Samter's Immunologic Diseases,. 2001; 81:1067-1085.

Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
View in: PubMed

Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
View in: PubMed

Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
View in: PubMed

Cytokine gene expression in human cardiac allograft recipients. Transpl Immunol. 1994 Sep; 2(3):199-207.
View in: PubMed

Cytokine gene expression in human lung transplant recipients. Transplantation. 1993 Oct; 56(4):956-61.
View in: PubMed

Cytokine gene expression in rejecting cardiac allografts. Transplantation. 1992 Aug; 54(2):326-32.
View in: PubMed

Murine memory B cells are multi-isotype expressors. Immunology. 1991 Jan; 72(1):48-55.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 520C
Boston, MA 02215
Get Directions

Top